Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: JOHN W. who wrote (894)	7/8/1997 1:52:00 PM
From: JOHN W.	of 6136

Just some info that I have not seen here so I thought someone might care about the numbers: 1. IMS reported data for the week ending 6/27/97: -New scips: 3,011 up 17% rel to prior week of 2,580. -Total refills:3,182 up 17% rel to prior week of 2,709. -Total scrips: 6,193 up 17% rel to prior week of 5,289. 2. Overall total scrips for PI(s) were down 6%. The other PI(s) were down or insignificant growth. It is obvious that Viracept accounted for all the growth in the PI market 3. My calculations estimate: 26-28% for Total scrips and approx 20-22% for new scrips. 4. Next week's data should show weaker numbers for all PI (s) due to the July 4th Holiday. 5. The International Workshop On HIV Drug Resistance, Treatment Strategies and Eradication conference in St. Petersburg, FL (June 25-28) reiterated/validated facts posted in the thread on why Viracept must be used as the first line PI. Why has no one brought this up? I have some of my notes on this conference (propably old news to most of you) that I can post if anyone is interested. Regards, John.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next